Zobrazeno 1 - 8
of 8
pro vyhledávání: '"A N Lud"'
Publikováno v:
Современная онкология, Vol 12, Iss 2, Pp 54-60 (2010)
Externí odkaz:
https://doaj.org/article/2f2e2228b3dc4b939f52e1d34b2af795
Publikováno v:
Современная онкология, Vol 11, Iss 3, Pp 50-54 (2009)
Внедрение в клиническую практику большого количества эффективных схем цитостатической терапии позволило, с одной стороны, сделать изл
Externí odkaz:
https://doaj.org/article/4b75e30e4d584f1dab4a73f2dcf93114
Autor:
T. E. Tikhomirova, A. S. Tyulyandina, A. A. Rumyantsev, M. E. Abramov, A. Yu. Anokhin, A. N. Lud, S. A. Tjulandin
Publikováno v:
Pelvic Surgery and Oncology. 12:56-62
Ovarian cancer is a heterogeneous disease and is the leading cause of mortality among all gynecological malignancies. The disease is characterized by a high frequency of germline and somatic mutations in BRCA1/2 suppressor genes, which, according to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12d37635f3d6bcd5254996419b37e26c
https://doi.org/10.17650/2686-9594-2022-12-3-56-62
https://doi.org/10.17650/2686-9594-2022-12-3-56-62
Publikováno v:
Immunopathology, Allergology, Infectology. :6-20
The objective of this study was to investigate DNase, various types of proteolytic and oxidoreductase serum and abzyme activities, as well as the serum contents of free DNA in patients with breast tumors in accordance with the clinical, pathological
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56f72b9d28f38f520782c37db54097fe
https://doi.org/10.14427/jipai.2022.3.6
https://doi.org/10.14427/jipai.2022.3.6
Autor:
A. A. Rumyantsev, A. S. Tyulyandina, I. A. Pokataev, E. R. Israelyan, M. Е. Abramov, H. N. Lud, S. A. Tyulyandin
Publikováno v:
Meditsinskiy sovet = Medical Council. :77-83
Introduction. Olaparib is the only PARP inhibitor approved in Russia for the maintenance therapy for BRCA-positive ovarian cancer after frontline chemotherapy. We conducted a real-world analysis of olaparib efficacy and safety for this indication.Aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8585de7541f936a4510c28544ba83d3
https://doi.org/10.21518/2079-701x-2022-16-9-77-83
https://doi.org/10.21518/2079-701x-2022-16-9-77-83
Autor:
O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Ganshina, G. V. Vyshinskaya, M. A. Kazantseva, M. V. Sukhova, O. E. Ryabishina, E. V. Lubennikova, D. A. Filonenko, E. I. Chichikov, I. N. Polushkina, E. I. Borisova, A. N. Lud, A. A. Meshcheryakov
Publikováno v:
Opuholi Ženskoj Reproduktivnoj Sistemy, Vol 16, Iss 2, Pp 25-37 (2020)
Background. Treatment results for the patients with stage II–III triple negative breast cancer (TN BC) have to be improved. Not only the new treatment regimens, but new predictive and prognostic factors should to be developed.Materials and methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7f92e118d6a66c2de25ee5a7622ae12
https://ojrs.abvpress.ru/ojrs/article/view/732
https://ojrs.abvpress.ru/ojrs/article/view/732
Autor:
E. V. Lubennikova, I. P. Ganshina, A. N. Lud, D. V. Komov, I. V. Kolyadina, Y. V. Vishnevskaya, I. K. Vorotnikov, D. L. Stroyakovsky, N. A. Savelov, V. F. Semiglazov, А. G. Manikhas, А. V. Osheychik, T. B. Strelnikova, K. R. Zeynalova, L. G. Zhukova
Publikováno v:
Медицинский совет, Vol 0, Iss 14, Pp 40-45 (2017)
The HannaH study showed that neoadjuvante-adjuvant subcutaneous and intravenous trastuzumab have similar efficacy and tolerability in patients with early HER2-positive breast cancer. The analysis of the results of the subcutaneous and intravenous tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::552904f1560094f061be248fd3319088
https://doi.org/10.21518/2079-701x-2017-14-40-45
https://doi.org/10.21518/2079-701x-2017-14-40-45
Publikováno v:
Медицинский совет, Vol 0, Iss 6, Pp 84-86 (2017)
Gastric cancer is one of the leading causes of death among all cancers in Russia. Progression-free and overall survival cannot be drastically changed by current therapeutic approaches. There is a strong need in new drugs for that disease. Teysuno has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07fd74e0aead005f98f1c895bb0e8bb3
https://www.med-sovet.pro/jour/article/view/1890
https://www.med-sovet.pro/jour/article/view/1890